Interleukin-28 as a Promising Marker for Predicting Invasive Mechanical Ventilation Requirement and Mortality in COVID-19 Patients

OBJECTIVE: The study aimed to evaluate serum interleukin-28 levels in COVID-19 patients and correlate the results with disease severity.MATERIAL AND METHODS: This study included 90 patients who presented to the COVID-19 outpatient clinics, hospital wards, and intensive care units. Serum interleukin-28, C-reactive protein, lactate dehydrogenase, fibrinogen, D-dimer, and ferritin levels were mea-sured. Patients were divided into 3 groups based on clinical severity to mild, moderate, and severe groups (each group consisted of 30 patients).RESULTS: There were significant differences in serum C-reactive protein, lactate dehydrogenase, fibrinogen, D-dimer, ferritin, and inter-leukin-28 levels between all groups. The mean serum interleukin-28 levels of all patients were 383.74 +/- 63.58 ng/L. The mean serum interleukin-28 levels were 335.52 +/- 42.12 ng/L in the mild group, 366.88 +/- 41.27 ng/L in the moderate group, and 453.46 +/- 36.78 ng/L in the severe group.CONCLUSION: There were significant differences in comparisons of all pairs (P < .05). Interleukin-28 may be a promising biomarker for detecting disease severity in COVID-19 patients.

Journal

THORACIC RESEARCH AND PRACTICE

Year

2023

Volume

24

Issue

2

Pages

61-65

eISSN

2979-9139

DOI

10.5152/ThoracResPract.2023.22146

WoS UID

WOS:001011106100002